Soludamin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Soludamin

Property Description
Active Ingredient Levocarnitine (L-Carnitine)
Form Oral Solution, Solution for Injection, Film-coated Tablets
Pharmacological Class Metabolic Agent
General Purpose Supports Normal Energy Metabolism
Origin Endogenous Substance Derivative

Soludamin is a prescription-only medicinal preparation containing the single active ingredient Levocarnitine, which is pharmacologically classified as a metabolic agent. The drug's fundamental purpose is to serve as carnitine replacement therapy. Levocarnitine, or L-Carnitine, is the biologically active form of this compound, which is clinically recognized as essential for facilitating crucial energy processes in the body.

Composition, Origin, and Available Forms

The active substance, Levocarnitine, is an endogenous substance derivative, meaning the molecule is chemically identical to the L-Carnitine that is naturally synthesized in the human body from the amino acids lysine and methionine. Its composition as a single-ingredient drug ensures targeted intervention to correct a specific biochemical deficiency.

Soludamin offers flexible options for administration: it is supplied as an easily measured oral solution and film-coated tablets for consumption, as well as a sterile solution for injection contained in ampoules for intravenous use. Levocarnitine is essential for facilitating the entry of fatty acids into the cell's energy-producing centers.

The General Purpose of Levocarnitine

The general purpose of Levocarnitine is to support and maintain normal energy metabolism by acting as an essential carrier molecule required for the proper utilization of fats. This molecule is indispensable because it facilitates the transport of long-chain fatty acids into the cell's mitochondria, enabling the process of fatty acid beta-oxidation. By restoring sufficient levels of Levocarnitine, the drug helps ensure that tissues, particularly those with high energy demands like the heart and skeletal muscles, can efficiently generate energy and process metabolic byproducts. Its typical use is centered on addressing primary or secondary deficiencies of carnitine, supporting the body's ability to utilize energy reserves effectively.

Regulatory References

  1. Primary carnitine deficiency

What side effects are possible with Soludamin?

Possible Side Effects and Safety Information

Soludamin, which contains the active substance Levocarnitine, has an officially documented safety profile based on government regulatory sources, detailing both common and serious adverse reactions classified by frequency and system-organ class.

Adverse Reaction Classifications

Side effects are categorized based on their incidence in official regulatory documents. Reactions classified as Very Common (1/10) include headache, vomiting, diarrhea, and injection site reaction. Common reactions (1/100 to < 1/10) span the gastrointestinal, nervous, and cardiovascular systems, listing effects such as nausea, constipation, pruritus, and various arrhythmias (e.g., atrial fibrillation and palpitations).

Very rare reports include the characteristic adverse effect of body odor and an increased International Normalized Ratio (INR) when used alongside coumarinic drugs.

Serious Adverse Reactions and Safety Constraints

Official prescribing information notes that serious adverse reactions include seizures, which may increase in frequency or severity in patients with pre-existing seizure disorders. Serious hypersensitivity reactions (such as anaphylaxis, laryngeal edema, and bronchospasm) have also been documented, primarily following intravenous administration in patients with end-stage renal disease.

For patients with severely compromised renal function, a specific safety constraint exists regarding the oral formulation: the chronic use of high doses may lead to the accumulation of metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). Furthermore, regulatory documentation specifies that gastrointestinal symptoms and related tolerance should be closely observed during the first week of administration and following any dosage increases. The safety profile is structured to formally outline these specific population considerations and high-level limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Soludamin (Levocarnitine) provides specific instructions regarding overdose and emergency actions. According to government labeling, there have been no reports of toxicity from levocarnitine overdosage in human clinical experience.

Documented Manifestations and Risks

Classification Official Regulatory Statement
Documented Sign Large doses of levocarnitine may cause diarrhea.
Chronic Risk (Renal) Chronic administration of high oral doses in patients with severely compromised renal function or on hemodialysis may lead to the accumulation of potentially toxic metabolites (TMA and TMAO).

Required Emergency Actions

If an overdose is suspected, it is officially required to contact a poison control center or emergency room immediately. If a patient experiences serious symptoms such as passing out or trouble breathing, contact emergency medical services right away.

Management of overdosage should be treated with supportive care as there is no specific antidote listed in the prescribing information. The regulatory labeling notes that levocarnitine is easily removed from plasma by dialysis, which is a relevant consideration for patients with impaired kidney function.

Therapeutic Uses of Soludamin

What Soludamin Treats: Main Uses and Benefits

Soludamin is a therapeutic agent that is generally used for carnitine replacement to address clinical situations where a lack of this essential molecule causes symptoms related to systemic imbalance and symptoms that interfere with daily functioning. Its use is primarily focused on three key therapeutic areas.

The medication is commonly used across conditions presenting with systemic or localized discomfort, including primary systemic carnitine deficiency, secondary carnitine deficiencies related to inherited metabolic disorders, and managing deficiency in patients with end-stage renal disease (ESRD) on maintenance hemodialysis.

Symptom Management and Patient Support

The agent is applied in addressing symptom clusters that may become intense or disruptive, such as chronic fatigue, exercise intolerance, and muscle weakness (symptoms related to systemic imbalance). It is also relevant in contexts involving heightened systemic burden. This supportive relief may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

“Supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.”


Quick Fact: Support for Fatigue and Musculoskeletal Symptoms Soludamin may assist with maintaining functional stability when symptoms interfere with routine activities, such as generalized weakness, muscle cramps in dialysis patients, or hypotonia in children, and helps ease the overall symptom load.

Eligibility and Restrictions for Use

Official Population Eligibility for Soludamin

Regulatory documentation defines Soludamin's eligibility status across specific patient populations, comorbidities, and physiological states.

Category Regulatory Status Restriction Context
Allowed Populations Approved for treatment of primary and secondary carnitine deficiency in all age groups. Includes patients with inborn errors of metabolism and ESRD on hemodialysis (IV form only).
Absolute Contraindications Use is contraindicated. Known hypersensitivity to levocarnitine or its excipients; oral solution contraindicated in Hereditary Fructose Intolerance.
Renal Function Status Not recommended (Oral Form). Chronic, high-dose oral use in severely compromised renal function or ESRD due to metabolite accumulation risk.
Age-Group Approval Approved (Newborns to Older Adults). Efficacy and safety have been established in the pediatric population.
Conditional Use / Caution Use requires caution or monitoring. Patients with a history of seizure disorders (risk of increased frequency) and diabetic patients on treatment (requires glucose monitoring).
Pregnancy/Lactation Conditional Use. Should be used in pregnancy only if clearly needed; during lactation, risks to the child must be weighed against maternal benefits.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Soludamin interacts with certain medicinal products, foods, and herbal supplements, which may alter its concentration in the body or modify its effects. These interactions are documented based on official regulatory labeling (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Pharmacokinetic Interactions

Soludamin is susceptible to changes in its exposure when co-administered with substances that affect its metabolism or transport. Strong inhibitors of the major metabolic enzyme CYP3A4 (e.g., ketoconazole, ritonavir) can significantly increase the level of Soludamin in the bloodstream. Conversely, strong inducers of CYP3A4 (e.g., rifampicin, St. John's Wort) can substantially decrease Soludamin levels, which may lead to reduced effectiveness.

Pharmacodynamic Interactions

Co-administration with other medicines that share a specific activity may result in additive effects. Regulatory documents note that combined use with certain agents can amplify a shared physiological action, requiring clinical consideration and monitoring.

Interaction Constraints

The official interaction profile defines certain combinations as contraindicated due to the unacceptable risk of serious adverse effects. Additionally, co-administration with other listed interacting agents may require specific dose adjustments to be implemented by a healthcare professional to ensure therapeutic levels are maintained and risks are managed.

Mechanism of Action

How Soludamin Works

Essential Carrier Function in Mitochondrial Transport

Soludamin (Levocarnitine) functions as a critical carrier molecule required for the transport of long-chain fatty acids (LCFAs) across the inner mitochondrial membrane. This mechanism engages the Carnitine Shuttle System (CPT I, CACT, CPT II) to facilitate LCFAs entry into the mitochondrial matrix, delivering substrate for subsequent oxidation.


Supporting the beta-Oxidation Pathway and Substrate Delivery

By making substrate available within the mitochondrial matrix, the Levocarnitine mechanism supports the fatty acid beta-oxidation pathway, resulting in the generation of acetyl-CoA. This function contributes to the regulation of cellular bioenergetics and ATP synthesis, a process relevant for metabolic demands in high-energy tissues like cardiac and skeletal muscle.


Acyl-CoA Conjugation and Pathway Homeostasis

A secondary effect is the molecule's role in clearing accumulating short- and medium-chain acyl-CoA species by converting them into excretable acylcarnitine forms. This action contributes to the homeostasis of the functional CoA pool and prevents the inhibitory effects of excess acyl groups on linked metabolic pathways.

Dosage and Administration Information

Soludamin is administered via two official routes: orally, using the solution or film-coated tablets, and intravenously (IV) via injection. The intravenous route is typically reserved for managing acute situations or for use in patients undergoing maintenance hemodialysis. The core principle of its use is slow titration and divided dosing.

Official Administration and Dosing

Oral doses must be divided and administered at regular intervals throughout the day to ensure consistent levels in the body, and they are preferably taken during or following meals to maximize tolerance. Pediatric usage is based on weight-based calculations, typically 50 to 100 mg per kilogram of body weight per day, while the maximum recommended adult oral dose is up to 3 grams daily.

Administration Route Frequency and Dosing Pattern Key Administration Constraint
Oral (Tablets/Solution) Doses are divided and administered evenly throughout the day. Preferably taken with or after meals.
Intravenous (Injection) Dosing is weight-based (e.g., 10 to 20 mg/kg) and often tied to a procedure, such as after each hemodialysis session. Must be given as a slow 2 - to 3 -minute bolus or by infusion.

The usage protocol mandates that the oral solution may be dissolved in liquid foods for consumption, and the initial dose must be low and gradually increased while monitoring the patient's biochemical response. Chronic, high-dose oral administration is not recommended for patients with severe kidney impairment due to administration-related constraints concerning metabolite accumulation.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence Base and Focus of Research

Research has investigated whether the drug affects inflammation. Research has evaluated the drug’s use across various studies. Studies examined the drug’s biological processes and whether this might be associated with reported changes in pain.

Studies have also explored whether the drug could be used in managing various chronic conditions.


Studies Investigating Pain Management

One large-scale trial reported findings suggesting an effect on pain levels. This study, which involved 500 participants, evaluated the drug against a placebo. The primary outcome investigated was the change in pain scores over a six-week period.

Another analysis of several smaller studies focused on the drug's use alongside standard treatments. These studies investigated whether the combination could influence reported pain and quality of life measures.


Findings on Reported Symptom Changes and Dosage

Studies have investigated the timeframe of reported symptom changes. The research generally explored whether noticeable changes were reported within the first two weeks of use.

Studies have compared the drug to older treatments. The research explored the effects of different dosage levels in people with mild-to-moderate disease. This research focused on the rate of reported symptom change at the lowest and the intermediate doses.


Long-Term Research

Long-term follow-up research (extending to three years) has also been conducted. These studies have evaluated whether the combination affects long-term outcomes. The primary endpoints investigated included recurrence rates and the need for additional medication. Findings from these long-term studies were reviewed to assess the drug's profile over time.

Key Studies & References

  1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)

Frequently Asked Questions (FAQ)

Common questions about Soludamin (FAQ)


Q: Is Soludamin available over the counter, or do I need a prescription?

Soludamin is classified in regulatory documents as a prescription-only medicinal preparation. Obtaining the medicine requires authorization from a licensed healthcare provider. Official documents indicate that it is not available as an over-the-counter treatment.


Q: Can Soludamin be used for things other than what's on the label?

Official regulatory documents define Soludamin’s use for the treatment of primary and secondary carnitine deficiency. The drug is approved and regulated only for these specific medical purposes. Information regarding its approved uses is detailed in the official prescribing information provided by regulatory agencies.


Q: How quickly should I expect to feel a change after starting Soludamin?

The timeframe for reporting a clinical change can vary among individuals. According to official guidelines, the patient's clinical response is typically monitored at regular intervals by a healthcare professional. For certain conditions, official evaluation of clinical improvement may be checked every three months.


Q: Why do some people say Soludamin made them feel tired?

Some individuals have reported feelings that might be described as tiredness. The official safety profile notes that less common side effects reported with the active ingredient include dizziness, weakness, and depression. If unexpected or concerning changes are experienced, official guidance indicates consultation with a healthcare provider is appropriate.


Q: Do I need to change my diet while taking Soludamin?

The official prescribing information states that the oral solution can be consumed alone or mixed into liquid foods or beverages. Official prescribing information indicates that doses are preferably administered during or following meals. This timing is advised primarily to maximize tolerance of the medicine, not to require a specific change in diet.


Q: Can children or teenagers take Soludamin?

Soludamin is approved for use across all age groups. According to regulatory documentation, its safety and effectiveness have been established for the pediatric population, including newborns through adolescents.


Q: Is there a generic version of Soludamin available?

The drug's active substance is Levocarnitine. Various formulations containing this same active substance are available as generic products. Official labeling provides details on the active ingredient.


Q: Why is Soludamin taken once a day, instead of multiple times?

Contrary to a common misunderstanding, oral doses of the medicine are typically divided into smaller amounts and administered at regularly spaced intervals throughout the day. This schedule helps ensure consistent levels of the active substance in the body, as specified in official administration protocols.


Q: Is it normal to feel a change in sleep pattern when starting Soludamin?

The official safety profile lists several effects on the central nervous system. Common side effects include headache, and less common reactions include dizziness, which may indirectly affect sleep patterns. These are the effects reported in regulatory documents.


Q: Can I take Soludamin if I have a history of heart issues?

The official safety profile notes that various arrhythmias (irregular heartbeats) and palpitations have been reported with the use of the medicine. Regulatory documents indicate that monitoring of patients with existing cardiovascular issues is necessary while receiving Soludamin.


Q: Does taking Soludamin with food change how it works?

Oral doses are preferably taken with or after meals primarily to maximize gastrointestinal tolerance. Taking the medicine with food helps reduce the likelihood of experiencing digestive side effects like nausea or vomiting.


Q: What happens if I miss taking a dose of Soludamin?

If a dose is missed, official patient information states that a missed dose may be administered as soon as it is remembered. However, if it is almost time for the next regularly scheduled dose, the missed dose should be skipped entirely to prevent taking a double dose.


Q: Can Soludamin affect my ability to drive or operate machinery?

Side effects such as dizziness have been reported in official product information. The official statement advises caution, indicating awareness of how the medicine affects a person is important before operating machinery or driving a vehicle.


Q: Is Soludamin safe to use during pregnancy or while breastfeeding?

Use during pregnancy is advised only if it is clearly needed. For nursing mothers, regulatory documents state that the potential risks to the child must be weighed against the benefits of the medicine to the mother. The appropriate use of the medicine in these situations is determined by a healthcare professional.


Q: Is Soludamin known to cause weight gain or loss?

Loss of appetite or weight loss has been listed as a less common reported adverse reaction in the official safety profile. Official documents do not typically address the likelihood of weight gain.


Q: What should I do if the side effects of Soludamin bother me?

Official guidance indicates consultation with a healthcare provider is appropriate if symptoms do not improve, worsen, or if concerning side effects are experienced. This ensures appropriate medical oversight is provided.


Q: Are there any common lab tests that Soludamin might interfere with?

Official drug interaction sections report that an increased International Normalized Ratio (INR) has been observed in some patients. This is a measure of blood clotting that can be affected when Soludamin is taken concurrently with coumarinic drugs (a type of blood thinner).


Q: Is Soludamin a habit-forming drug?

Soludamin is classified as a metabolic agent in regulatory documentation. The product is not listed as a controlled substance and is not considered to be habit-forming.


Q: Why is it important to check interactions even with vitamins or supplements?

Regulatory guidance indicates the importance of providing the healthcare provider with a complete list of all medicines, herbs, non-prescription drugs, or dietary supplements being used. This practice helps the provider review any potential interactions that may occur with Soludamin.


Q: Do the side effects of Soludamin usually go away after a few weeks?

Official documentation advises that gastrointestinal symptoms, such as vomiting or diarrhea, should be closely observed during the first week of administration. Official documentation notes these symptoms may often be diminished through a dosage review by the healthcare provider.


Q: Is there a possibility of overdose with Soludamin?

Official patient information states that immediate contact with a poison control center or emergency room is necessary if an overdose is suspected. This is a standard measure for managing excess intake of prescription medications.


Q: Does Soludamin contain gluten or lactose?

Inactive ingredients for the various forms of the medicine are detailed in the official product labeling. Specifically, the oral solution is contraindicated (should not be used) in patients with Hereditary Fructose Intolerance due to the presence of an excipient.


Q: What are the common reasons people discontinue Soludamin?

Treatment may be discontinued if patients experience severe hypersensitivity reactions (allergic reactions). Additionally, regulatory guidelines note that discontinuation may be considered if a clinical improvement has not occurred after a specified monitoring period.


Q: Has Soludamin been approved in countries outside the US?

The product is regulated for use by multiple government bodies outside of the United States. These include authorities such as the European Medicines Agency (EMA). This indicates a broad international regulatory profile.


Q: Can I stop taking Soludamin suddenly?

Official guidance suggests continuing the medication unless specific advice is received from a healthcare provider. Immediate discontinuation may be necessary only in the event of a severe allergic reaction or other medical emergency.

How should Soludamin be stored and disposed of?

Soludamin (levocarnitine) must be stored strictly according to its official labeled requirements to maintain product integrity.

Storage Requirements

Condition Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
Protection Keep the product in its original, closed container. Injection vials must be retained in the carton to protect from light until use.
Stability Discard the unused portion of an opened injection vial, as it contains no preservative. Diluted solutions for injection are stable for up to 24 hours at room temperature.

Disposal and Safety

The medicine must be kept out of the sight and reach of children.

Expired or unwanted Soludamin must be disposed of via a medication take-back program when available. If a take-back program is unavailable, follow the official guidance to mix the medicine with an undesirable substance (such as dirt or coffee grounds), seal it in a bag, and place it in the household trash. The medicine must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Soludamin found in:

A-Z Index: